Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1424224rdf:typepubmed:Citationlld:pubmed
pubmed-article:1424224lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:1424224lifeskim:mentionsumls-concept:C0001792lld:lifeskim
pubmed-article:1424224lifeskim:mentionsumls-concept:C0012315lld:lifeskim
pubmed-article:1424224lifeskim:mentionsumls-concept:C0015772lld:lifeskim
pubmed-article:1424224lifeskim:mentionsumls-concept:C0036043lld:lifeskim
pubmed-article:1424224lifeskim:mentionsumls-concept:C0857121lld:lifeskim
pubmed-article:1424224pubmed:issue6lld:pubmed
pubmed-article:1424224pubmed:dateCreated1992-12-8lld:pubmed
pubmed-article:1424224pubmed:abstractTextFelodipine is a new dihydropyridine calcium channel blocker with a number of properties that enhance its suitability as a first-line antihypertensive drug for the elderly. Felodipine has a 100-fold selectivity for inhibiting the contribution of vascular smooth muscle compared with cardiac muscle. Negative inotropic action appears minimal while selectivity appears to increase with age. Felodipine has a minimal effect on smooth muscle of venous capacitance vessels, thereby greatly reducing the likelihood of orthostatic hypotension. Renal effects are favorable; the glomerular filtration rate is increased in some patients. The extended-release formulation of felodipine produces a smooth 24-hour plasma concentration curve and is effective when prescribed once daily. Felodipine appears to lower blood pressure effectively in the elderly patient with few, generally mild, adverse effects.lld:pubmed
pubmed-article:1424224pubmed:languageenglld:pubmed
pubmed-article:1424224pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1424224pubmed:citationSubsetIMlld:pubmed
pubmed-article:1424224pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1424224pubmed:statusMEDLINElld:pubmed
pubmed-article:1424224pubmed:issn0730-0077lld:pubmed
pubmed-article:1424224pubmed:authorpubmed-author:DeQuattroVVlld:pubmed
pubmed-article:1424224pubmed:issnTypePrintlld:pubmed
pubmed-article:1424224pubmed:volume14lld:pubmed
pubmed-article:1424224pubmed:ownerNLMlld:pubmed
pubmed-article:1424224pubmed:authorsCompleteYlld:pubmed
pubmed-article:1424224pubmed:pagination965-87lld:pubmed
pubmed-article:1424224pubmed:dateRevised2008-2-12lld:pubmed
pubmed-article:1424224pubmed:meshHeadingpubmed-meshheading:1424224-...lld:pubmed
pubmed-article:1424224pubmed:meshHeadingpubmed-meshheading:1424224-...lld:pubmed
pubmed-article:1424224pubmed:meshHeadingpubmed-meshheading:1424224-...lld:pubmed
pubmed-article:1424224pubmed:meshHeadingpubmed-meshheading:1424224-...lld:pubmed
pubmed-article:1424224pubmed:meshHeadingpubmed-meshheading:1424224-...lld:pubmed
pubmed-article:1424224pubmed:meshHeadingpubmed-meshheading:1424224-...lld:pubmed
pubmed-article:1424224pubmed:year1992lld:pubmed
pubmed-article:1424224pubmed:articleTitleEfficacy and safety of felodipine, a new dihydropyridine calcium channel blocker, in elderly hypertensive patients.lld:pubmed
pubmed-article:1424224pubmed:affiliationUniversity of Southern California School of Medicine, Los Angeles.lld:pubmed
pubmed-article:1424224pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1424224pubmed:publicationTypeReviewlld:pubmed